Related Experiment Videos
Calcium antagonist nimodipine in intractable epilepsy
F A de Falco1, U Bartiromo, L Majello
1Department of Neurophysiology, 2nd School of Medicine, University of Naples, Italy.
Epilepsia
|March 1, 1992
Summary
Nimodipine, a calcium channel blocker, may offer anticonvulsant benefits for patients with intractable epilepsy. This study found that nimodipine reduced seizure frequency in a significant portion of participants, suggesting its potential as an adjunctive epilepsy treatment.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Calcium ion (Ca2+) influx into neurons is implicated in the development of epileptic seizures.
- Calcium entry blockers are being investigated for potential anticonvulsant properties.
Purpose of the Study:
- To evaluate the efficacy of nimodipine, a calcium antagonist, as an adjunctive therapy in patients with intractable epilepsy.
Main Methods:
- A total of 21 patients with intractable epilepsy due to organic brain lesions received nimodipine (30 mg, t.i.d.) alongside their existing antiepileptic drug (AED) regimen.
- Seizure frequency was monitored over a 12-week treatment period.
Main Results:
- 67% of patients (14 out of 21) experienced a reduction in seizure frequency.
- 38% of patients (8 out of 21) showed a decrease in seizure frequency exceeding 40%.
- No significant changes were observed in AED or electrolyte serum levels; one patient experienced lowered blood pressure.
Conclusions:
- Nimodipine demonstrated a positive effect on seizure frequency reduction in patients with intractable epilepsy.
- The findings suggest nimodipine's potential as an adjunctive treatment for epilepsy, warranting further investigation.